Xenomics Announces License With Warnex Of Acute Myeloid Leukemia Assay

Xenomics, Inc. (Pink Sheets:XNOM, FWB:XE7) announces that it has granted Warnex Medical Laboratories, a division of Warnex Inc., nonexclusive rights in Canada to offer NPM1 testing as a laboratory service for the diagnosis, stratification and monitoring of patients with Acute Myeloid Leukemia (AML). AML is a clinically heterogeneous disease with about 200,000 new cases per year worldwide. The disease subgrouping by karyotypic abnormalities indicates patient prognosis.

More: continued here

Filed under: Lymphoma / Leukemia on February 26th, 2008